Study Condition(s): Kidney Disease
A Study of LY3113593 in Participants With Chronic Kidney Disease
Study Alias: FEAC
The purpose of this study is to determine the safety of the study drug, LY3113593. The study will also evaluate how much of the study drug gets into the blood stream, how long it takes the body to remove the study drug, and what effect the study drug has on the body. This study is not intended to treat anemia of chronic kidney disease. Participants will receive up to four injections of LY3113593 or placebo into a vein.
The results of this study are not yet available.
Here you can find out a bit more about the requirements for volunteers who took part in this study
Participant must be receiving hemodialysis at least 3 times per week for at least 4 months
Participant must be receiving ESA (erythropoiesis stimulating agent) injections for at least 4 weeks and are willing to stop the injections for approximately 8 weeks
Participant must not be currently participating in another clinical trial
Participant must not have completed another clinical trial within the last 30 days
Participant must not have previously participated in this clinical trial